Century Therapeutics (IPSC) Stock: Buy, Sell, or Hold?
IPSC - Century Therapeutics, Inc. Common Stock
$1.58
-0.03 (-1.86%)
âŧ
5d:
+5.33%
30d:
-10.23%
90d:
-25.12%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 12, 2026
20d
Get Alerted When IPSC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: IPSC is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: IPSC is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: IPSC is currently trading at $1.58, which is considered fair relative to its 30-day fair value range of $1.42 to $1.82.
Technical Outlook: Technically, IPSC is in a strong downtrend. Immediate support is located at $1.31, while resistance sits at $1.75.
Market Sentiment: IPSC scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.75 (+195.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IPSC is in a strong downtrend. Immediate support is located at $1.31, while resistance sits at $1.75.
Market Sentiment: IPSC scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.75 (+195.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.42 -
$1.82
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 195.0% below Wall St target ($4.75)
- WARNING: Composite score 33/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.42 -
$1.82
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.31
Resistance Level
$1.75
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.58
Wall Street Target
$4.75
(+195.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 22, 2026 4:12 PM ET
Data refreshes hourly during market hours. Next update: 5:12 PM
Data refreshes hourly during market hours. Next update: 5:12 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IPSC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 56 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 49 HOLD |
|
TRVI
Trevi Therapeutics Inc |
STRONG BUY
11 analysts |
$28 | 69 BUY |
